<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158182</url>
  </required_header>
  <id_info>
    <org_study_id>DI/14/107/03/028</org_study_id>
    <nct_id>NCT02158182</nct_id>
  </id_info>
  <brief_title>Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding</brief_title>
  <official_title>Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether lactulose, L-ornithine L-aspartate, and
      rifaximin are effective in the prevention of the development of hepatic encephalopathy in
      cirrhotic patients with acute variceal bleeding
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of clinical hepatic encephalopathy</measure>
    <time_frame>7 days</time_frame>
    <description>Determined by West-Haven Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of minimal hepatic encephalopathy</measure>
    <time_frame>7 days</time_frame>
    <description>Determined by psychometric hepatic encephalopathy score (PHES) and critical flicker frequency (CFF)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Development of adverse effects</measure>
    <time_frame>7 days</time_frame>
    <description>Side or adverse effect will be defined as an undesirable secondary effect which occurs in addition to the desired therapeutic effect of a drug or medication.
Non serious side effect will be defined as an undesirable secondary effect that does not represents a risk for patient´s life or function.
Particularly we will addressed: Diarrhea, bloating, nausea, vomiting, elevation of serum creatinine, flatulence, abdominal pain, constipation, headache, dizziness
Serious side effect will be defined as an undesirable secondary effect that represents a risk for patient´s life or function.
Particularly we will addressed: allergic reactions.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L-ornithine L-aspartate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days</description>
    <arm_group_label>lactulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ornithine L-aspartate</intervention_name>
    <description>10 grams by intravenous way for 24 hours. Duration of therapy: 7 days</description>
    <arm_group_label>L-ornithine L-aspartate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>2 tablets (400mg) three times daily. Duration of therapy: 7 days</description>
    <arm_group_label>Rifaximin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.
Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.
Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Cirrhotic patients with acute variceal bleeding, without minimal or clinical hepatic
        encephalopathy according to PHES, CFF and West-Haven criteria

        Exclusion Criteria:

          -  Age under 18 year-old or over 65 year-old, with any other neuropsychiatric disorder or
             dementia, presence of active bacterial or fungal infections, receiving antibiotics for
             any cause, previous diagnosis of hepatic encephalopathy and receiving therapy with
             lactulose, rifaximin, L-ornithine L-aspartate, source of bleeding different from
             variceal origin, serum creatinine greater than 2.0 mg/dl or with chronic renal
             failure. Therapy in the previous six months with any of the drugs that will be used in
             this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General de Mexico</name>
      <address>
        <city>Mexico City</city>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>May 19, 2018</last_update_submitted>
  <last_update_submitted_qc>May 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>MARIA DE FATIMA HIGUERA DE LA TIJERA</investigator_full_name>
    <investigator_title>MD, MSc.</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Acute Variceal Bleeding</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Lactulose</mesh_term>
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

